Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Depressive Disorder in Pregnancy Clear all
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Depression

NCT04211467
View directory record Official record
Conditions
Depression, Clinical Depression, Depression, Anxiety, Depression, Postpartum, Depression, Endogenous, Depression in Remission, Depression Chronic, Depression Moderate, Depression Severe
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation

NCT01492309
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active Transcranial Magnetic Simulation, Sham Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Jul 23, 2026, 2:42 AM EDT
Completed No phase listed Observational

A Pilot Study of Prophylactic Management of Lamotrigine in Pregnant Women

NCT03774641
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Schizo Affective Disorder
Interventions
Lamictal
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NCT02614547
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

NCT02942004
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Postpartum Video Education in High Risk Populations

NCT06310720
View directory record Official record
Conditions
Postpartum Hemorrhage, Postpartum Depression, Postpartum Sepsis, Postpartum Preeclampsia, Patient Empowerment, Patient Education, Postpartum Care
Interventions
Video Education
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Lexapro in the Treatment of Patients With Postpartum Depression

NCT00277108
View directory record Official record
Conditions
Postpartum Depression
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Jul 23, 2026, 2:42 AM EDT
Terminated Not applicable Interventional Results available

Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset

NCT01842542
View directory record Official record
Conditions
Depression, Postpartum
Interventions
NeuroStar Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Neuronetics
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Hartford, Connecticut • Gainesville, Florida • Pensacola, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

NCT02285504
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)

NCT06979154
View directory record Official record
Conditions
Antenatal Depression, Major Depressive Disorder, Major Depressive Disorder in Pregnancy, Healthy Controls
Interventions
tACS (aperiodic)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 2:42 AM EDT
Terminated No phase listed Observational

A Prospective Study of Postpartum Depression in Women With Major Depression

NCT01328613
View directory record Official record
Conditions
Postpartum Depression
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

NCT04442503
View directory record Official record
Conditions
Depression, Postpartum
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
68
States / cities
Scottsdale, Arizona • Bentonville, Arkansas • Anaheim, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

NCT02978326
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Jul 23, 2026, 2:42 AM EDT
Withdrawn Not applicable Interventional

Duloxetine for the Treatment of Postpartum Depression

NCT00617045
View directory record Official record
Conditions
Postpartum Depression, Major Depressive Disorder
Interventions
duloxetine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Jul 23, 2026, 2:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Perinatal Depression Treatment in a Pediatric Setting- Pilot Phase

NCT00804739
View directory record Official record
Conditions
Postpartum Depression
Interventions
Mother-Infant Treatment Team
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Jul 23, 2026, 2:42 AM EDT
Terminated Phase 4 Interventional Results available

Bupropion for Depression in ESRD Patients on Hemodialysis

NCT02238977
View directory record Official record
Conditions
Major Depression, End Stage Renal Disease
Interventions
Fluoxetine, Bupropion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

NCT06057012
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
BRII-296, Depo Medrol
Drug
Lead sponsor
Brii Biosciences Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
11
States / cities
Sherman Oaks, California • Torrance, California • Boynton Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

NCT06285916
View directory record Official record
Conditions
Depression, Postpartum, Postpartum Depression, Post-partum Depression, Postnatal Depression, Post-Natal Depression
Interventions
NORA520 Dose 1, NORA520 Dose 2, Placebo
Drug
Lead sponsor
DuKang Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Bentonville, Arkansas • Anaheim, California • Canoga Park, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 23, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD

NCT06979544
View directory record Official record
Conditions
Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression
Interventions
LPCN 1154A, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
18
States / cities
Anahiem, California • Canoga Park, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 23, 2026, 2:42 AM EDT